The initial therapeutic response in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab contributes to the change of liver function during treatment: A multicenter analysis
{{output}}
Background: Therapeutic response in patients with unresectable hepatocellular carcinoma (HCC) receiving multikinase inhibitors is associated with changes in liver function. However, limited data are available for patients treated... ...
